SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
sox040713 Member Profile
 
Followed By 42
Posts 4,417
Boards Moderated 1
Alias Born 11/04/11
160x600 placeholder
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 9/22/2017 6:02:17 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 9/11/2017 12:47:10 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/11/2017 6:04:38 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/11/2017 6:04:37 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/6/2017 6:27:18 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/6/2017 6:24:45 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 8/8/2017 4:18:08 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:17:33 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:17:00 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:16:36 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/13/2017 4:04:10 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/7/2017 4:19:05 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/9/2017 4:09:09 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 4/28/2017 12:50:45 PM
Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance "InvestorsHub NewsWire" - 4/17/2017 7:03:27 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/31/2017 4:25:24 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 3/29/2017 4:13:08 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/27/2017 11:29:27 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/16/2017 7:01:38 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 2/9/2017 4:04:17 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/9/2017 9:39:24 AM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/4/2017 3:58:28 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/15/2016 6:25:29 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/9/2016 6:06:41 AM
Amended Annual Report (10-k/a) "Edgar (US Regulatory)" - 10/28/2016 5:02:25 PM
sox040713   Sunday, 09/24/17 05:24:48 PM
Re: None
Post # of 200968 
IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents

Upcoming Milestones

\

Past Milestones

Kevetrin

- Positive primary endpoint and p21 data (Phase 1)
http://www.ipharminc.com/press-release/2016/11/12/assay-results-from-cellceutix-phase-1-clinical-trial-of-kevetrin-for-cancer-show-increased-p21-expression-in-675-of-evaluable-patients

- Orphan drug designation for ovarian cancer
http://www.ipharminc.com/press-release/2016/11/16/cellceutixs-kevetrin-receives-fda-orphan-drug-designation-for-the-treatment-of-ovarian-cancer

- Orphan drug designation for pancreatic cancer
http://www.ipharminc.com/press-release/2016/11/12/cellceutix-receives-fda-orphan-drug-designation-for-kevetrin-for-the-treatment-of-pancreatic-cancer

- Orphan drug designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-receives-fda-orphan-drug-designmation-for-kevetrin-for-the-treatment-of-retinoblastoma

- Rare pediatric disease designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-receives-rare-pediatric-disease-designation-from-fda-for-kevetrin-for-the-treatment-of-retinoblastoma

Brilacidin

- B-UP positive top-line data (Phase 2 POC)
http://www.ipharminc.com/press-release/2017/7/13/innovation-pharmaceuticals-phase-2-poc-trial-for-inflammatory-bowel-disease-achieves-induction-of-remission-in-a-majority-of-patients-treated-with-brilacidin

- B-OM encouraging interim data (Phase 2)
http://www.ipharminc.com/press-release/2017/3/27/cellceutix-reports-very-encouraging-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-severe-oral-mucositis-om-in-head-and-neck-cancer-patients-high-potential-for-preventative-treatment

- B-ABSSSI positive top-line data (Phase 2b)
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin

- QIDP designation for B-ABSSSI
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda

- Fast track designation for B-OM
http://www.ipharminc.com/press-release/2016/11/16/fda-grants-fast-track-designation-to-cellceutixs-brilacidin-om-for-oral-mucositis

- MTA extension for prophylactic testing in implanted devices
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-completes-lab-testing-of-brilacidin-for-planned-phase-3-trial-for-acute-bacterial-skin-and-skin-structure-infections

- Formulation stable at room temperature
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-breakthrough-in-the-formulation-of-novel-antibiotic-brlaicidin-plans-studies-to-treat-diabetic-foot-ulcers

- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/AAC.02955-14#corresp-1

Prurisol

- Positive top-line data (Phase 2a)
http://www.ipharminc.com/press-release/2016/11/12/cellceutix-phase-2-trial-of-prurisol-for-mild-to-moderate-psoriasis-meets-primary-endpoint

- Positive primary endpoint (Phase 1)
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-anti-psoriasis-drug-prurisol-meets-primary-endpoint-of-clinical-trial

- 505(b)(2) pathway
http://www.ipharminc.com/press-release/2016/11/17/cellceutix-informed-by-fda-that-505b2-approval-would-be-an-acceptable-approach-for-its-psoriasis-drug

Clinical Trials

1. K-OC (Phase 2a, Recruiting)
https://clinicaltrials.gov/ct2/show/NCT03042702?term=cellceutix&rank=1

2. P (Phase 1, Completed)
https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=2

3. B-OM (Phase 2, Active, not recruiting)
https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3

4. P (Phase 2a, Completed)
https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=4

5. P (Phase 2b, Active, not recruiting)
https://clinicaltrials.gov/ct2/show/NCT02949388?term=cellceutix&rank=5

6. B-ABSSSI (Phase 2b, Completed)
https://clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=6

7. K (Phase 1, Completed)
https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=7

8. B-UP (Phase 2 POC, Completed)
http://www.ipharminc.com/press-release/2016/11/10/cellceutix-receives-update-on-first-patient-enrollment-in-phase-2-proof-of-concept-study-of-brilacidin-for-ulcerative-proctitis

Pipeline

\

Recent Interviews

- 2017 Q3 Conference Call Transcript
https://seekingalpha.com/article/4080068-innovation-pharmaceuticals-ipix-ceo-leo-ehrlich-q3-2017-results-earnings-call-transcript

- 2017 Q1 Conference Call Transcript
http://seekingalpha.com/article/4023682-cellceutix-corporation-ctix-ceo-leo-ehrlich-q1-2017-results-earnings-call-transcript

- Interview with New Cellceutix President Dr A Bertolino
http://seekingalpha.com/article/3988240-interview-new-cellceutix-president-dr-bertolino

- Cellceutix Pipeline Continues to Hit Milestone After Milestone
https://www.streetwisereports.com/pub/na/cellceutix-pipeline-continues-to-hit-milestone-after-milestone

- A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
http://www.thelifesciencesreport.com/pub/na/a-small-cap-biotech-with-big-ideas-for-acute-infections-and-cancers-cellceutixs-leo-ehrlich-and-dr-daniel-jorgensen

Corporate Overview

- BioCentury NewsMakers Conference https://static1.squarespace.com/static/5715352e20c647639137f992/t/59b2f34946c3c498ebfe112e/1504899917915/IPIX+Company+Presentation+BioCentury+NewsMakers+Conference++8Sep2017.pdf

- Drug Discovery and Therapy World Congress
https://static1.squarespace.com/static/5715352e20c647639137f992/t/596cac7df14aa1a6e7118ed8/1500294274057/IPI+DDTWC+Brilacidin+presentation+%28final-u%29+13Jul2017.pdf

- July 2017
https://static1.squarespace.com/static/5715352e20c647639137f992/t/5967d1c92994ca6bed362ade/1499976142099/2017+July+IPIX+Corporate+Overview.pdf

Patents

- Kevetrin
https://www.google.com/patents/US8338454

- Brilacidin
https://www.sec.gov/Archives/edgar/data/1355250/000147793214002418/ctix_ex1037.htm
https://www.google.com/patents/US20160243117
https://www.google.com/patents/EP2709619A2

- Prurisol
https://www.google.com/patents/WO2013103601A1

MP Advisors Report

https://drive.google.com/file/d/0Bz15O4eaX-asWVpoclB2WUhENFk/view

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
OC – ovarian cancer
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product



FUD - Fear, uncertainty and doubt, is generally a strategic attempt to influence perception by disseminating negative and dubious or false information.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist